GlassScriptPhysician profile
Martin E Koutcher
NPI 1023024460
$21,209.73
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $2,397.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $16,620.15 | 2019 | |
| Mallinckrodt Hospital Products INC. | $1,811.53 | 2020 | |
| Amgen INC. | $447.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $441.07 | 2019-2020 | |
| Genzyme Corporation | $282.91 | 2019-2020 | |
| Genentech USA, INC. | $271.48 | 2019 | |
| Celgene Corporation | $222.20 | 2019 | |
| Abbvie INC. | $221.59 | 2019-2020 | |
| Lilly USA, LLC | $201.66 | 2019-2020 | |
| Pfizer INC. | $188.65 | 2019-2020 | |
| Glaxosmithkline, LLC. | $145.00 | 2019-2020 | |
| Radius Health, INC. | $120.27 | 2019 | |
| Medexus Pharma, INC. | $63.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $62.28 | 2019-2020 | |
| Ucb, INC. | $45.66 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $19.44 | 2020 | |
| Avion Pharmaceuticals | $17.64 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.38 | 2020 | |
| Horizon Therapeutics Plc | $12.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Koutcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.